View all cases
UPC CFI 165/2024
Apr 9, 2024·EP3805248 +1 more: PROCESS FOR CONCENTRATION OF ANTIBODIES AND THERAPEUTIC PRODUCTS THEREOF
- Case details
- StatusCase ClosedActionProvisional measuresCategoryProvisional Measures
- Parties
- ClaimantsReps: Frank-Erich Hufnagel (Freshfields Bruckhaus Deringer); Kilian Seidel (Freshfields Bruckhaus Deringer); Cameron Marshall (Carpmaels & Ransford); Joanna Rowley (Carpmaels & Ransford)
- Division
- Dusseldorf LD
- Technology
- Organic Chemistry
- Language
- English
Decisions
- 2024-09-06PI deniedApplication for provisional measures
Order of Düsseldorf Local Division rejecting Novartis/Genentech's application for provisional measures against Celltrion Healthcare entities regarding EP 3 805 248 B1 (biosimilar product Epysqli). The court found the requirements for provisional measures were not met and ordered Novartis/Genentech to pay interim costs of EUR 138,562.80. The court set out important headnotes on: the interpretation of Art. 25 and 62 UPCA as autonomous uniform law; the concept of imminent infringement; group company liability; inapplicability of R. 295 RoP to provisional measures applications; and parties' obligation to present focused technical arguments.
Legal issues:Autonomous interpretation of Art. 25 and Art. 62(1) UPCAImminent infringement as basis for provisional measuresGroup company liability in distribution networksInapplicability of R. 295 RoP (stay) to provisional measuresClaim interpretation obligation on parties
Documents
| Document title | Date | Public |
|---|---|---|
| Case Closure Formal Check | 2025-03-27 | Not public |
| Headnote-and-Keywords | 2024-09-06 | Not public |
| Measures_DecisionOutcome_Notification.pdf | 2024-09-06 | Not public |
| Final Order on PI Application | 2024-09-06 | Public |
| Final Order on PI Application | 2024-09-06 | Not public |
| 18492-2024_OH_DUS-LOC_UPC202407310930AM_S03 | 2024-09-06 | Not public |
| 18492-2024_OH_DUS-LOC_UPC202407310930AM_S04 | 2024-09-06 | Not public |
| 18492-2024_OH_DUS-LOC_UPC202407310930AM_S04 | 2024-09-06 | Not public |
| 18492-2024_OH_DUS-LOC_UPC202407310930AM_S02 | 2024-09-06 | Not public |
| 18492-2024_OH_DUS-LOC_UPC202407310930AM_S01 | 2024-09-06 | Not public |
| 18492-2024_OH_DUS-LOC_UPC202407310930AM_S03 | 2024-09-06 | Not public |
| 18492-2024_OH_DUS-LOC_UPC202407310930AM_S01 | 2024-09-06 | Not public |
| 18492-2024_OH_DUS-LOC_UPC202407310930AM_S02 | 2024-09-06 | Not public |
| Receipt | 2024-09-03 | Not public |
| Exhibit FBD 46 | 2024-09-03 | Not public |
| Submission of EPO preliminary opinion | 2024-09-03 | Not public |
| Time limits for parties' oral submissions | 2024-07-24 | Public |
| Acknowledgement-of-lodging | 2024-06-27 | Not public |
| BB49 Expert declaration Dr. L. de Leede of 26 June 2024 | 2024-06-27 | Not public |
| BB38 Higher Regional Court Dusseldorf judgment of 2009 2012 (I 2 U 44 12) | 2024-06-27 | Not public |
| BB49a CV of Dr. L. de Leede | 2024-06-27 | Not public |
| BB41 Witness Statement Bart Buiks | 2024-06-27 | Not public |
| BB46 Cacia et al Biochemistry 1996 Vol 35 No 6 p 1897 1903 | 2024-06-27 | Not public |
| BB38a English machine translation of Exhibit BB38 | 2024-06-27 | Not public |
| BB39 Witness Statement Taeksang Kwon | 2024-06-27 | Not public |
| BB43 Witness Statement of DongKyu Kim | 2024-06-27 | Not public |
| BB49b Annexes to expert declaration dr. L. de Leede of 26 June 2024 | 2024-06-27 | Not public |
| BB47 Presta et al J Immunol 1993 Vol 151 No 5 p 2623 2632 | 2024-06-27 | Not public |
| BB43a Exhibit 1 to Witness Statement of Dongkyu Kim | 2024-06-27 | Not public |
| BB45a CV of Prof. dr. T. Dingermann | 2024-06-27 | Not public |
| BB42 Witness Statement Annelies van Leeuwen | 2024-06-27 | Not public |
| BB44a Annexes to Expert declaration of Prof. dr. H.W. Frijlink II | 2024-06-27 | Not public |
| BB45b Annexes to expert declaration of Prof. dr. T. Dingermann | 2024-06-27 | Not public |
| BB44 Expert declaration Prof. dr. H.W. Frijlink of 26 June 2024 (Expert declaration of Prof. dr. H.W. Frijlink II) | 2024-06-27 | Not public |
| BB40 Witness Statement Joel van Ruyskensvelde | 2024-06-27 | Not public |
| 20240627 Rejoinder UPC Celltrion v Novartis (signed) | 2024-06-27 | Not public |
| BB45 Expert declaration Prof. dr. T. Dingermann of 26 June 2024 | 2024-06-27 | Not public |
| BB48 Notice from the EPO regarding accelerated proceedings of 17 June 2024 | 2024-06-27 | Not public |
| Acknowledgement-of-lodging | 2024-06-27 | Not public |
| BB38 Higher Regional Court Dusseldorf judgment of 2009 2012 (I 2 U 44 12) | 2024-06-27 | Not public |
| BB39 Witness Statement Taeksang Kwon | 2024-06-27 | Not public |
| BB44 Expert declaration Prof. dr. H.W. Frijlink of 26 June 2024 (Expert declaration of Prof. dr. H.W. Frijlink II) | 2024-06-27 | Not public |
| 20240627 Rejoinder UPC Celltrion v Novartis (signed) | 2024-06-27 | Not public |
| BB49 Expert declaration Dr. L. de Leede of 26 June 2024 | 2024-06-27 | Not public |
| BB41 Witness Statement Bart Buiks | 2024-06-27 | Not public |
| BB48 Notice from the EPO regarding accelerated proceedings of 17 June 2024 | 2024-06-27 | Not public |
| BB47 Presta et al J Immunol 1993 Vol 151 No 5 p 2623 2632 | 2024-06-27 | Not public |
| BB45b Annexes to expert declaration of Prof. dr. T. Dingermann | 2024-06-27 | Not public |
| BB44a Annexes to Expert declaration of Prof. dr. H.W. Frijlink II | 2024-06-27 | Not public |
| BB45a CV of Prof. dr. T. Dingermann | 2024-06-27 | Not public |
| BB49a CV of Dr. L. de Leede | 2024-06-27 | Not public |
| BB40 Witness Statement Joel van Ruyskensvelde | 2024-06-27 | Not public |
| BB38a English machine translation of Exhibit BB38 | 2024-06-27 | Not public |
| BB43 Witness Statement of DongKyu Kim | 2024-06-27 | Not public |
| BB43a Exhibit 1 to Witness Statement of Dongkyu Kim | 2024-06-27 | Not public |
| BB42 Witness Statement Annelies van Leeuwen | 2024-06-27 | Not public |
| BB49b Annexes to expert declaration dr. L. de Leede of 26 June 2024 | 2024-06-27 | Not public |
| BB45 Expert declaration Prof. dr. T. Dingermann of 26 June 2024 | 2024-06-27 | Not public |
| BB46 Cacia et al Biochemistry 1996 Vol 35 No 6 p 1897 1903 | 2024-06-27 | Not public |
| Acknowledgement-of-lodging | 2024-06-27 | Not public |
| 20240627 Rejoinder UPC Celltrion v Novartis (signed) | 2024-06-27 | Not public |
| BB38 Higher Regional Court Düsseldorf judgment of 2009 2012 (I 2 U 44 12) | 2024-06-27 | Not public |
| BB48 Notice from the EPO regarding accelerated proceedings of 17 June 2024 | 2024-06-27 | Not public |
| BB45b Annexes to expert declaration of Prof. dr. T. Dingermann | 2024-06-27 | Not public |
| BB39 Witness Statement Taeksang Kwon | 2024-06-27 | Not public |
| BB47 Presta et al J Immunol 1993 Vol 151 No 5 p 2623 2632 | 2024-06-27 | Not public |
| BB45 Expert declaration Prof. dr. T. Dingermann of 26 June 2024 | 2024-06-27 | Not public |
| BB41 Witness Statement Bart Buiks | 2024-06-27 | Not public |
| BB44a Annexes to Expert declaration of Prof. dr. H.W. Frijlink II | 2024-06-27 | Not public |
| BB46 Cacia et al Biochemistry 1996 Vol 35 No 6 p 1897 1903 | 2024-06-27 | Not public |
| BB42 Witness Statement Annelies van Leeuwen | 2024-06-27 | Not public |
| BB49b Annexes to expert declaration dr. L. de Leede of 26 June 2024 | 2024-06-27 | Not public |
| BB49a CV of Dr. L. de Leede | 2024-06-27 | Not public |
| BB44 Expert declaration Prof. dr. H.W. Frijlink of 26 June 2024 (Expert declaration of Prof. dr. H.W. Frijlink II) | 2024-06-27 | Not public |
| BB38a English machine translation of Exhibit BB38 | 2024-06-27 | Not public |
| BB43 Witness Statement of DongKyu Kim | 2024-06-27 | Not public |
| BB49 Expert declaration Dr. L. de Leede of 26 June 2024 | 2024-06-27 | Not public |
| BB40 Witness Statement Joel van Ruyskensvelde | 2024-06-27 | Not public |
| BB43a Exhibit 1 to Witness Statement of Dongkyu Kim | 2024-06-27 | Not public |
| BB45a CV of Prof. dr. T. Dingermann | 2024-06-27 | Not public |
| Acknowledgement-of-lodging | 2024-06-27 | Not public |
| BB38 Higher Regional Court Dusseldorf judgment of 2009 2012 (I 2 U 44 12) | 2024-06-27 | Not public |
| BB41 Witness Statement Bart Buiks | 2024-06-27 | Not public |
| BB40 Witness Statement Joel van Ruyskensvelde | 2024-06-27 | Not public |
| BB45a CV of Prof. dr. T. Dingermann | 2024-06-27 | Not public |
| BB45b Annexes to expert declaration of Prof. dr. T. Dingermann | 2024-06-27 | Not public |
| BB42 Witness Statement Annelies van Leeuwen | 2024-06-27 | Not public |
| BB46 Cacia et al Biochemistry 1996 Vol 35 No 6 p 1897 1903 | 2024-06-27 | Not public |
| BB43a Exhibit 1 to Witness Statement of Dongkyu Kim | 2024-06-27 | Not public |
| BB39 Witness Statement Taeksang Kwon | 2024-06-27 | Not public |
| BB45 Expert declaration Prof. dr. T. Dingermann of 26 June 2024 | 2024-06-27 | Not public |
| BB48 Notice from the EPO regarding accelerated proceedings of 17 June 2024 | 2024-06-27 | Not public |
| BB49a CV of Dr. L. de Leede | 2024-06-27 | Not public |
| BB49b Annexes to expert declaration dr. L. de Leede of 26 June 2024 | 2024-06-27 | Not public |
| BB44 Expert declaration Prof. dr. H.W. Frijlink of 26 June 2024 (Expert declaration of Prof. dr. H.W. Frijlink II) | 2024-06-27 | Not public |
| BB43 Witness Statement of DongKyu Kim | 2024-06-27 | Not public |
| BB38a English machine translation of Exhibit BB38 | 2024-06-27 | Not public |
| BB49 Expert declaration Dr. L. de Leede of 26 June 2024 | 2024-06-27 | Not public |
| BB44a Annexes to Expert declaration of Prof. dr. H.W. Frijlink II | 2024-06-27 | Not public |
| 20240627 Rejoinder UPC Celltrion v Novartis (signed) | 2024-06-27 | Not public |
| BB47 Presta et al J Immunol 1993 Vol 151 No 5 p 2623 2632 | 2024-06-27 | Not public |
| Acknowledgement-of-lodging | 2024-06-27 | Not public |
| BB44a Annexes to Expert declaration of Prof. dr. H.W. Frijlink II | 2024-06-27 | Not public |
| BB43 Witness Statement of DongKyu Kim | 2024-06-27 | Not public |
| BB41 Witness Statement Bart Buiks | 2024-06-27 | Not public |
| BB49 Expert declaration Dr. L. de Leede of 26 June 2024 | 2024-06-27 | Not public |
| BB43a Exhibit 1 to Witness Statement of Dongkyu Kim | 2024-06-27 | Not public |
| BB49a CV of Dr. L. de Leede | 2024-06-27 | Not public |
| BB45a CV of Prof. dr. T. Dingermann | 2024-06-27 | Not public |
| BB45 Expert declaration Prof. dr. T. Dingermann of 26 June 2024 | 2024-06-27 | Not public |
| BB48 Notice from the EPO regarding accelerated proceedings of 17 June 2024 | 2024-06-27 | Not public |
| BB42 Witness Statement Annelies van Leeuwen | 2024-06-27 | Not public |
| BB40 Witness Statement Joel van Ruyskensvelde | 2024-06-27 | Not public |
| BB49b Annexes to expert declaration dr. L. de Leede of 26 June 2024 | 2024-06-27 | Not public |
| BB46 Cacia et al Biochemistry 1996 Vol 35 No 6 p 1897 1903 | 2024-06-27 | Not public |
| BB45b Annexes to expert declaration of Prof. dr. T. Dingermann | 2024-06-27 | Not public |
| BB38a English machine translation of Exhibit BB38 | 2024-06-27 | Not public |
| BB44 Expert declaration Prof. dr. H.W. Frijlink of 26 June 2024 (Expert declaration of Prof. dr. H.W. Frijlink II) | 2024-06-27 | Not public |
| 20240627 Rejoinder UPC Celltrion v Novartis (signed) | 2024-06-27 | Not public |
| BB38 Higher Regional Court Düsseldorf judgment of 2009 2012 (I 2 U 44 12) | 2024-06-27 | Not public |
| BB39 Witness Statement Taeksang Kwon | 2024-06-27 | Not public |
| BB47 Presta et al J Immunol 1993 Vol 151 No 5 p 2623 2632 | 2024-06-27 | Not public |
| Acknowledgement-of-lodging | 2024-06-27 | Not public |
| Acknowledgement-of-lodging | 2024-06-27 | Not public |
| BB45a CV of Prof. dr. T. Dingermann | 2024-06-27 | Not public |
| BB49a CV of Dr. L. de Leede | 2024-06-27 | Not public |
| BB48 Notice from the EPO regarding accelerated proceedings of 17 June 2024 | 2024-06-27 | Not public |
| BB46 Cacia et al Biochemistry 1996 Vol 35 No 6 p 1897 1903 | 2024-06-27 | Not public |
| BB38a English machine translation of Exhibit BB38 | 2024-06-27 | Not public |
| BB43a Exhibit 1 to Witness Statement of Dongkyu Kim | 2024-06-27 | Not public |
| BB43 Witness Statement of DongKyu Kim | 2024-06-27 | Not public |
| BB45 Expert declaration Prof. dr. T. Dingermann of 26 June 2024 | 2024-06-27 | Not public |
| BB42 Witness Statement Annelies van Leeuwen | 2024-06-27 | Not public |
| BB47 Presta et al J Immunol 1993 Vol 151 No 5 p 2623 2632 | 2024-06-27 | Not public |
| BB45b Annexes to expert declaration of Prof. dr. T. Dingermann | 2024-06-27 | Not public |
| BB49b Annexes to expert declaration dr. L. de Leede of 26 June 2024 | 2024-06-27 | Not public |
| BB41 Witness Statement Bart Buiks | 2024-06-27 | Not public |
| BB49 Expert declaration Dr. L. de Leede of 26 June 2024 | 2024-06-27 | Not public |
| BB44a Annexes to Expert declaration of Prof. dr. H.W. Frijlink II | 2024-06-27 | Not public |
| BB44 Expert declaration Prof. dr. H.W. Frijlink of 26 June 2024 (Expert declaration of Prof. dr. H.W. Frijlink II) | 2024-06-27 | Not public |
| BB38 Higher Regional Court Dusseldorf judgment of 2009 2012 (I 2 U 44 12) | 2024-06-27 | Not public |
| 20240627 Rejoinder UPC Celltrion v Novartis (signed) | 2024-06-27 | Not public |
| BB40 Witness Statement Joel van Ruyskensvelde | 2024-06-27 | Not public |
| BB39 Witness Statement Taeksang Kwon | 2024-06-27 | Not public |
| BB45b Annexes to expert declaration of Prof. dr. T. Dingermann | 2024-06-27 | Not public |
| BB43 Witness Statement of DongKyu Kim | 2024-06-27 | Not public |
| BB44 Expert declaration Prof. dr. H.W. Frijlink of 26 June 2024 (Expert declaration of Prof. dr. H.W. Frijlink II) | 2024-06-27 | Not public |
| BB49a CV of Dr. L. de Leede | 2024-06-27 | Not public |
| 20240627 Rejoinder UPC Celltrion v Novartis (signed) | 2024-06-27 | Not public |
| BB38 Higher Regional Court Düsseldorf judgment of 2009 2012 (I 2 U 44 12) | 2024-06-27 | Not public |
| BB49 Expert declaration Dr. L. de Leede of 26 June 2024 | 2024-06-27 | Not public |
| BB39 Witness Statement Taeksang Kwon | 2024-06-27 | Not public |
| BB47 Presta et al J Immunol 1993 Vol 151 No 5 p 2623 2632 | 2024-06-27 | Not public |
| BB41 Witness Statement Bart Buiks | 2024-06-27 | Not public |
| BB38a English machine translation of Exhibit BB38 | 2024-06-27 | Not public |
| BB44a Annexes to Expert declaration of Prof. dr. H.W. Frijlink II | 2024-06-27 | Not public |
| BB45a CV of Prof. dr. T. Dingermann | 2024-06-27 | Not public |
| BB45 Expert declaration Prof. dr. T. Dingermann of 26 June 2024 | 2024-06-27 | Not public |
| BB46 Cacia et al Biochemistry 1996 Vol 35 No 6 p 1897 1903 | 2024-06-27 | Not public |
| BB49b Annexes to expert declaration dr. L. de Leede of 26 June 2024 | 2024-06-27 | Not public |
| BB48 Notice from the EPO regarding accelerated proceedings of 17 June 2024 | 2024-06-27 | Not public |
| BB43a Exhibit 1 to Witness Statement of Dongkyu Kim | 2024-06-27 | Not public |
| BB40 Witness Statement Joel van Ruyskensvelde | 2024-06-27 | Not public |
| BB42 Witness Statement Annelies van Leeuwen | 2024-06-27 | Not public |
| Outcome of the Order | 2024-06-14 | Not public |
| 2024-06-14 Procedural Order | 2024-06-14 | Public |
| Template-Order | 2024-06-14 | Not public |
| Receipt | 2024-06-07 | Not public |
| Receipt | 2024-06-07 | Not public |
| 24-06-06 - Application pursuant to R. 262.2 RoP UPC | 2024-06-07 | Not public |
| Exhibit FBD 38 (CONF) | 2024-06-07 | Not public |
| Exhibit FBD 41 | 2024-06-07 | Not public |
| 24-06-06 - Xolair - EP 248 - vs Celltrion EU - Reply | 2024-06-07 | Not public |
| Exhibit FBD 40 (CONF) | 2024-06-07 | Not public |
| Application pursuant to R. 9 RoP UPC | 2024-06-07 | Not public |
| Exhibit FBD 44 | 2024-06-07 | Not public |
| Exhibit FBD 36 (CONF) | 2024-06-07 | Not public |
| Exhibit FBD 36a (CONF) | 2024-06-07 | Not public |
| Exhibit FBD 37 (CONF) | 2024-06-07 | Not public |
| Exhibit FBD 39 (CONF) | 2024-06-07 | Not public |
| Exhibit FBD 36a (CONF) | 2024-06-07 | Not public |
| Exhibit FBD 38 (CONF) | 2024-06-07 | Not public |
| 24-06-06 - Xolair - EP 248 - vs Celltrion EU - Reply | 2024-06-07 | Not public |
| Exhibit FBD 37 (CONF) | 2024-06-07 | Not public |
| Exhibit FBD 36 (CONF) | 2024-06-07 | Not public |
| Exhibit FBD 42 | 2024-06-07 | Not public |
| Exhibit FBD 43 | 2024-06-07 | Not public |
| Exhibit FBD 35 | 2024-06-07 | Not public |
| Exhibit FBD 45a | 2024-06-07 | Not public |
| Exhibit FBD 34 | 2024-06-07 | Not public |
| Exhibit FBD 40 (CONF) | 2024-06-07 | Not public |
| Exhibit FBD 45 | 2024-06-07 | Not public |
| Exhibit FBD 39 (CONF) | 2024-06-07 | Not public |
| summons | 2024-05-16 | Not public |
| Procedural Order Oral Hearing | 2024-05-16 | Public |
| Document technical reason | 2024-05-16 | Public |
| Panel-Appointment | 2024-05-16 | Not public |
| BB23 - EP 4 104 859 A1 | 2024-05-14 | Not public |
| BB27 - Statement of Defence by Novartis in the Dutch proceedings 3 April 2024 | 2024-05-14 | Not public |
| BB26N - Notice Examiner 31 January 2022 | 2024-05-14 | Not public |
| BB33 - WO 03072060 A2 | 2024-05-14 | Not public |
| BB26M - Letter Novartis regarding third party observation 4 October 2021 | 2024-05-14 | Not public |
| BB34 - WO 9006764 A1 | 2024-05-14 | Not public |
| BB21 - Expert declaration of Prof. dr. H.W. Frijlink on arginine(-HCl) (Expert declaration of Prof. Frijlink I) | 2024-05-14 | Not public |
| BB26B - Letter EPO to remedy deficiencies (submission of claims) 28 October 2020 | 2024-05-14 | Not public |
| BB26C - Claims 1-21 submitted by letter of Novartis 3 November 2020 | 2024-05-14 | Not public |
| BB26I - Tomar et al. journal of the Taylor Francis Group 2017 vol. 9 p. 476-489 submitted by letter of Novartis 26 July | 2024-05-14 | Not public |
| BB22 - Technical primer for the Patent | 2024-05-14 | Not public |
| BB26K - Yadav et al. Pharmaceutical Research 2011 vol. 28 p. 1750-1764 submitted by letter of Novartis 26 July 2021 (Yad | 2024-05-14 | Not public |
| BB26G - Letter Novartis regarding the adjustment of the claims 26 July 2021 | 2024-05-14 | Not public |
| BB35 - JP H04-198195 | 2024-05-14 | Not public |
| BB20 - EP 2 116 265 B1 | 2024-05-14 | Not public |
| BB26A - International search report 12 April 2006 | 2024-05-14 | Not public |
| BB35A - JP H04-198195 - translation of description | 2024-05-14 | Not public |
| BB29 - EP 1 610 820 B2 | 2024-05-14 | Not public |
| BB26E - European Search Opinion 10 June 2021 | 2024-05-14 | Not public |
| BB26D - Letter Novartis on submission of claims 1-21 3 November 2020 | 2024-05-14 | Not public |
| BB21B - Annexes to the expert declaration of Prof. dr. H.W. Frijlink | 2024-05-14 | Not public |
| BB26H - Adjusted claims 1-3 by letter of Novartis 26 July 2021 | 2024-05-14 | Not public |
| BB26L - Third party observation 22 September 2021 | 2024-05-14 | Not public |
| BB32 - EP 0 025 275 A2 | 2024-05-14 | Not public |
| BB30 - Crommelin Pharmaceutical Biotechnology Fundamentals and Applications (second edition) | 2024-05-14 | Not public |
| BB28 - Letter Novartis regarding submission of patentees 18 July 2022 | 2024-05-14 | Not public |
| BB26O - Third party observation 24 May 2022 | 2024-05-14 | Not public |
| 20240515 Objection UPC Celltrion v Novartis (signed) | 2024-05-14 | Not public |
| BB25 - Decision of the Board of Appeal EPO on EP 636 5 May 2022 | 2024-05-14 | Not public |
| BB24 - EP 4 108 259 A1 | 2024-05-14 | Not public |
| BB36 - Hernandez et al. 2022 | 2024-05-14 | Not public |
| BB27A - English machine translation of Statement of Defence by Novartis 3 April 2024 | 2024-05-14 | Not public |
| BB26F - European Search Report 31 May 2021 | 2024-05-14 | Not public |
| BB31 - Chen et al. Pharmaceutical Research 2003 Vol. 20 No. 12 p. 1952-60 (Chen) | 2024-05-14 | Not public |
| BB37 - EP 1 786 830 B1 | 2024-05-14 | Not public |
| BB26J - Liu et al. Journal of Pharmaceutical Sciences 2005 vol. 94 p. 1928-1940 submitted by letter of Novartis 26 July | 2024-05-14 | Not public |
| BB21A - CV of Prof. dr. H.W. Frijlink | 2024-05-14 | Not public |
| BB26D - Letter Novartis on submission of claims 1-21 3 November 2020 | 2024-05-14 | Not public |
| BB26G - Letter Novartis regarding the adjustment of the claims 26 July 2021 | 2024-05-14 | Not public |
| BB36 - Hernandez et al. 2022 | 2024-05-14 | Not public |
| BB26C - Claims 1-21 submitted by letter of Novartis 3 November 2020 | 2024-05-14 | Not public |
| BB26M - Letter Novartis regarding third party observation 4 October 2021 | 2024-05-14 | Not public |
| BB22 - Technical primer for the Patent | 2024-05-14 | Not public |
| 20240515 Objection UPC Celltrion v Novartis (signed) | 2024-05-14 | Not public |
| BB21B - Annexes to the expert declaration of Prof. dr. H.W. Frijlink | 2024-05-14 | Not public |
| BB26F - European Search Report 31 May 2021 | 2024-05-14 | Not public |
| BB37 - EP 1 786 830 B1 | 2024-05-14 | Not public |
| BB27 - Statement of Defence by Novartis in the Dutch proceedings 3 April 2024 | 2024-05-14 | Not public |
| BB20 - EP 2 116 265 B1 | 2024-05-14 | Not public |
| BB24 - EP 4 108 259 A1 | 2024-05-14 | Not public |
| BB26I - Tomar et al. journal of the Taylor Francis Group 2017 vol. 9 p. 476-489 submitted by letter of Novartis 26 July | 2024-05-14 | Not public |
| BB26O - Third party observation 24 May 2022 | 2024-05-14 | Not public |
| BB26K - Yadav et al. Pharmaceutical Research 2011 vol. 28 p. 1750-1764 submitted by letter of Novartis 26 July 2021 (Yad | 2024-05-14 | Not public |
| BB26N - Notice Examiner 31 January 2022 | 2024-05-14 | Not public |
| BB31 - Chen et al. Pharmaceutical Research 2003 Vol. 20 No. 12 p. 1952-60 (Chen) | 2024-05-14 | Not public |
| BB26E - European Search Opinion 10 June 2021 | 2024-05-14 | Not public |
| BB23 - EP 4 104 859 A1 | 2024-05-14 | Not public |
| BB29 - EP 1 610 820 B2 | 2024-05-14 | Not public |
| BB35A - JP H04-198195 - translation of description | 2024-05-14 | Not public |
| BB30 - Crommelin Pharmaceutical Biotechnology Fundamentals and Applications (second edition) | 2024-05-14 | Not public |
| BB34 - WO 9006764 A1 | 2024-05-14 | Not public |
| BB35 - JP H04-198195 | 2024-05-14 | Not public |
| BB32 - EP 0 025 275 A2 | 2024-05-14 | Not public |
| BB21 - Expert declaration of Prof. dr. H.W. Frijlink on arginine(-HCl) (Expert declaration of Prof. Frijlink I) | 2024-05-14 | Not public |
| BB27A - English machine translation of Statement of Defence by Novartis 3 April 2024 | 2024-05-14 | Not public |
| BB25 - Decision of the Board of Appeal EPO on EP 636 5 May 2022 | 2024-05-14 | Not public |
| BB26L - Third party observation 22 September 2021 | 2024-05-14 | Not public |
| BB33 - WO 03072060 A2 | 2024-05-14 | Not public |
| BB28 - Letter Novartis regarding submission of patentees 18 July 2022 | 2024-05-14 | Not public |
| BB26J - Liu et al. Journal of Pharmaceutical Sciences 2005 vol. 94 p. 1928-1940 submitted by letter of Novartis 26 July | 2024-05-14 | Not public |
| BB26H - Adjusted claims 1-3 by letter of Novartis 26 July 2021 | 2024-05-14 | Not public |
| BB21A - CV of Prof. dr. H.W. Frijlink | 2024-05-14 | Not public |
| BB26B - Letter EPO to remedy deficiencies (submission of claims) 28 October 2020 | 2024-05-14 | Not public |
| BB26A - International search report 12 April 2006 | 2024-05-14 | Not public |
| BB26E - European Search Opinion 10 June 2021 | 2024-05-14 | Not public |
| BB24 - EP 4 108 259 A1 | 2024-05-14 | Not public |
| BB33 - WO 03072060 A2 | 2024-05-14 | Not public |
| BB21A - CV of Prof. dr. H.W. Frijlink | 2024-05-14 | Not public |
| BB30 - Crommelin Pharmaceutical Biotechnology Fundamentals and Applications (second edition) | 2024-05-14 | Not public |
| BB29 - EP 1 610 820 B2 | 2024-05-14 | Not public |
| BB27 - Statement of Defence by Novartis in the Dutch proceedings 3 April 2024 | 2024-05-14 | Not public |
| BB32 - EP 0 025 275 A2 | 2024-05-14 | Not public |
| BB26G - Letter Novartis regarding the adjustment of the claims 26 July 2021 | 2024-05-14 | Not public |
| 20240515 Objection UPC Celltrion v Novartis (signed) | 2024-05-14 | Not public |
| BB27A - English machine translation of Statement of Defence by Novartis 3 April 2024 | 2024-05-14 | Not public |
| BB26K - Yadav et al. Pharmaceutical Research 2011 vol. 28 p. 1750-1764 submitted by letter of Novartis 26 July 2021 (Yad | 2024-05-14 | Not public |
| BB26J - Liu et al. Journal of Pharmaceutical Sciences 2005 vol. 94 p. 1928-1940 submitted by letter of Novartis 26 July | 2024-05-14 | Not public |
| BB36 - Hernandez et al. 2022 | 2024-05-14 | Not public |
| BB26D - Letter Novartis on submission of claims 1-21 3 November 2020 | 2024-05-14 | Not public |
| BB26H - Adjusted claims 1-3 by letter of Novartis 26 July 2021 | 2024-05-14 | Not public |
| BB31 - Chen et al. Pharmaceutical Research 2003 Vol. 20 No. 12 p. 1952-60 (Chen) | 2024-05-14 | Not public |
| BB26L - Third party observation 22 September 2021 | 2024-05-14 | Not public |
| BB35A - JP H04-198195 - translation of description | 2024-05-14 | Not public |
| BB23 - EP 4 104 859 A1 | 2024-05-14 | Not public |
| BB20 - EP 2 116 265 B1 | 2024-05-14 | Not public |
| BB21B - Annexes to the expert declaration of Prof. dr. H.W. Frijlink | 2024-05-14 | Not public |
| BB26C - Claims 1-21 submitted by letter of Novartis 3 November 2020 | 2024-05-14 | Not public |
| BB22 - Technical primer for the Patent | 2024-05-14 | Not public |
| BB26B - Letter EPO to remedy deficiencies (submission of claims) 28 October 2020 | 2024-05-14 | Not public |
| BB37 - EP 1 786 830 B1 | 2024-05-14 | Not public |
| BB26M - Letter Novartis regarding third party observation 4 October 2021 | 2024-05-14 | Not public |
| BB34 - WO 9006764 A1 | 2024-05-14 | Not public |
| BB28 - Letter Novartis regarding submission of patentees 18 July 2022 | 2024-05-14 | Not public |
| BB26F - European Search Report 31 May 2021 | 2024-05-14 | Not public |
| BB26I - Tomar et al. journal of the Taylor Francis Group 2017 vol. 9 p. 476-489 submitted by letter of Novartis 26 July | 2024-05-14 | Not public |
| BB26A - International search report 12 April 2006 | 2024-05-14 | Not public |
| BB35 - JP H04-198195 | 2024-05-14 | Not public |
| BB26N - Notice Examiner 31 January 2022 | 2024-05-14 | Not public |
| BB21 - Expert declaration of Prof. dr. H.W. Frijlink on arginine(-HCl) (Expert declaration of Prof. Frijlink I) | 2024-05-14 | Not public |
| BB26O - Third party observation 24 May 2022 | 2024-05-14 | Not public |
| BB25 - Decision of the Board of Appeal EPO on EP 636 5 May 2022 | 2024-05-14 | Not public |
| BB26J - Liu et al. Journal of Pharmaceutical Sciences 2005 vol. 94 p. 1928-1940 submitted by letter of Novartis 26 July | 2024-05-14 | Not public |
| BB26L - Third party observation 22 September 2021 | 2024-05-14 | Not public |
| BB27 - Statement of Defence by Novartis in the Dutch proceedings 3 April 2024 | 2024-05-14 | Not public |
| BB30 - Crommelin Pharmaceutical Biotechnology Fundamentals and Applications (second edition) | 2024-05-14 | Not public |
| BB27A - English machine translation of Statement of Defence by Novartis 3 April 2024 | 2024-05-14 | Not public |
| BB26H - Adjusted claims 1-3 by letter of Novartis 26 July 2021 | 2024-05-14 | Not public |
| BB26B - Letter EPO to remedy deficiencies (submission of claims) 28 October 2020 | 2024-05-14 | Not public |
| BB21B - Annexes to the expert declaration of Prof. dr. H.W. Frijlink | 2024-05-14 | Not public |
| BB26A - International search report 12 April 2006 | 2024-05-14 | Not public |
| BB26D - Letter Novartis on submission of claims 1-21 3 November 2020 | 2024-05-14 | Not public |
| BB22 - Technical primer for the Patent | 2024-05-14 | Not public |
| BB32 - EP 0 025 275 A2 | 2024-05-14 | Not public |
| BB21A - CV of Prof. dr. H.W. Frijlink | 2024-05-14 | Not public |
| BB28 - Letter Novartis regarding submission of patentees 18 July 2022 | 2024-05-14 | Not public |
| BB35A - JP H04-198195 - translation of description | 2024-05-14 | Not public |
| BB24 - EP 4 108 259 A1 | 2024-05-14 | Not public |
| BB20 - EP 2 116 265 B1 | 2024-05-14 | Not public |
| BB26G - Letter Novartis regarding the adjustment of the claims 26 July 2021 | 2024-05-14 | Not public |
| BB37 - EP 1 786 830 B1 | 2024-05-14 | Not public |
| BB26C - Claims 1-21 submitted by letter of Novartis 3 November 2020 | 2024-05-14 | Not public |
| BB26E - European Search Opinion 10 June 2021 | 2024-05-14 | Not public |
| BB36 - Hernandez et al. 2022 | 2024-05-14 | Not public |
| BB25 - Decision of the Board of Appeal EPO on EP 636 5 May 2022 | 2024-05-14 | Not public |
| BB34 - WO 9006764 A1 | 2024-05-14 | Not public |
| BB26K - Yadav et al. Pharmaceutical Research 2011 vol. 28 p. 1750-1764 submitted by letter of Novartis 26 July 2021 (Yad | 2024-05-14 | Not public |
| 20240515 Objection UPC Celltrion v Novartis (signed) | 2024-05-14 | Not public |
| BB26F - European Search Report 31 May 2021 | 2024-05-14 | Not public |
| BB29 - EP 1 610 820 B2 | 2024-05-14 | Not public |
| BB35 - JP H04-198195 | 2024-05-14 | Not public |
| BB33 - WO 03072060 A2 | 2024-05-14 | Not public |
| BB26I - Tomar et al. journal of the Taylor Francis Group 2017 vol. 9 p. 476-489 submitted by letter of Novartis 26 July | 2024-05-14 | Not public |
| BB21 - Expert declaration of Prof. dr. H.W. Frijlink on arginine(-HCl) (Expert declaration of Prof. Frijlink I) | 2024-05-14 | Not public |
| BB23 - EP 4 104 859 A1 | 2024-05-14 | Not public |
| BB26O - Third party observation 24 May 2022 | 2024-05-14 | Not public |
| BB26N - Notice Examiner 31 January 2022 | 2024-05-14 | Not public |
| BB26M - Letter Novartis regarding third party observation 4 October 2021 | 2024-05-14 | Not public |
| BB31 - Chen et al. Pharmaceutical Research 2003 Vol. 20 No. 12 p. 1952-60 (Chen) | 2024-05-14 | Not public |
| BB26L - Third party observation 22 September 2021 | 2024-05-14 | Not public |
| BB37 - EP 1 786 830 B1 | 2024-05-14 | Not public |
| BB26E - European Search Opinion 10 June 2021 | 2024-05-14 | Not public |
| BB26I - Tomar et al. journal of the Taylor Francis Group 2017 vol. 9 p. 476-489 submitted by letter of Novartis 26 July | 2024-05-14 | Not public |
| BB21B - Annexes to the expert declaration of Prof. dr. H.W. Frijlink | 2024-05-14 | Not public |
| BB26B - Letter EPO to remedy deficiencies (submission of claims) 28 October 2020 | 2024-05-14 | Not public |
| BB22 - Technical primer for the Patent | 2024-05-14 | Not public |
| BB26G - Letter Novartis regarding the adjustment of the claims 26 July 2021 | 2024-05-14 | Not public |
| BB20 - EP 2 116 265 B1 | 2024-05-14 | Not public |
| BB34 - WO 9006764 A1 | 2024-05-14 | Not public |
| BB26H - Adjusted claims 1-3 by letter of Novartis 26 July 2021 | 2024-05-14 | Not public |
| BB26M - Letter Novartis regarding third party observation 4 October 2021 | 2024-05-14 | Not public |
| BB30 - Crommelin Pharmaceutical Biotechnology Fundamentals and Applications (second edition) | 2024-05-14 | Not public |
| BB26C - Claims 1-21 submitted by letter of Novartis 3 November 2020 | 2024-05-14 | Not public |
| BB21 - Expert declaration of Prof. dr. H.W. Frijlink on arginine(-HCl) (Expert declaration of Prof. Frijlink I) | 2024-05-14 | Not public |
| BB26O - Third party observation 24 May 2022 | 2024-05-14 | Not public |
| BB32 - EP 0 025 275 A2 | 2024-05-14 | Not public |
| BB23 - EP 4 104 859 A1 | 2024-05-14 | Not public |
| BB35 - JP H04-198195 | 2024-05-14 | Not public |
| BB33 - WO 03072060 A2 | 2024-05-14 | Not public |
| BB26N - Notice Examiner 31 January 2022 | 2024-05-14 | Not public |
| BB21A - CV of Prof. dr. H.W. Frijlink | 2024-05-14 | Not public |
| BB26J - Liu et al. Journal of Pharmaceutical Sciences 2005 vol. 94 p. 1928-1940 submitted by letter of Novartis 26 July | 2024-05-14 | Not public |
| BB25 - Decision of the Board of Appeal EPO on EP 636 5 May 2022 | 2024-05-14 | Not public |
| BB29 - EP 1 610 820 B2 | 2024-05-14 | Not public |
| BB35A - JP H04-198195 - translation of description | 2024-05-14 | Not public |
| 20240515 Objection UPC Celltrion v Novartis (signed) | 2024-05-14 | Not public |
| BB24 - EP 4 108 259 A1 | 2024-05-14 | Not public |
| BB26D - Letter Novartis on submission of claims 1-21 3 November 2020 | 2024-05-14 | Not public |
| BB26A - International search report 12 April 2006 | 2024-05-14 | Not public |
| BB27 - Statement of Defence by Novartis in the Dutch proceedings 3 April 2024 | 2024-05-14 | Not public |
| BB31 - Chen et al. Pharmaceutical Research 2003 Vol. 20 No. 12 p. 1952-60 (Chen) | 2024-05-14 | Not public |
| BB26K - Yadav et al. Pharmaceutical Research 2011 vol. 28 p. 1750-1764 submitted by letter of Novartis 26 July 2021 (Yad | 2024-05-14 | Not public |
| BB27A - English machine translation of Statement of Defence by Novartis 3 April 2024 | 2024-05-14 | Not public |
| BB26F - European Search Report 31 May 2021 | 2024-05-14 | Not public |
| BB28 - Letter Novartis regarding submission of patentees 18 July 2022 | 2024-05-14 | Not public |
| BB36 - Hernandez et al. 2022 | 2024-05-14 | Not public |
| BB26N - Notice Examiner 31 January 2022 | 2024-05-14 | Not public |
| BB35A - JP H04-198195 - translation of description | 2024-05-14 | Not public |
| BB33 - WO 03072060 A2 | 2024-05-14 | Not public |
| BB26I - Tomar et al. journal of the Taylor Francis Group 2017 vol. 9 p. 476-489 submitted by letter of Novartis 26 July | 2024-05-14 | Not public |
| BB26E - European Search Opinion 10 June 2021 | 2024-05-14 | Not public |
| BB25 - Decision of the Board of Appeal EPO on EP 636 5 May 2022 | 2024-05-14 | Not public |
| BB26F - European Search Report 31 May 2021 | 2024-05-14 | Not public |
| BB35 - JP H04-198195 | 2024-05-14 | Not public |
| BB21B - Annexes to the expert declaration of Prof. dr. H.W. Frijlink | 2024-05-14 | Not public |
| BB27A - English machine translation of Statement of Defence by Novartis 3 April 2024 | 2024-05-14 | Not public |
| BB29 - EP 1 610 820 B2 | 2024-05-14 | Not public |
| BB21 - Expert declaration of Prof. dr. H.W. Frijlink on arginine(-HCl) (Expert declaration of Prof. Frijlink I) | 2024-05-14 | Not public |
| BB28 - Letter Novartis regarding submission of patentees 18 July 2022 | 2024-05-14 | Not public |
| BB26L - Third party observation 22 September 2021 | 2024-05-14 | Not public |
| BB26G - Letter Novartis regarding the adjustment of the claims 26 July 2021 | 2024-05-14 | Not public |
| BB26O - Third party observation 24 May 2022 | 2024-05-14 | Not public |
| BB36 - Hernandez et al. 2022 | 2024-05-14 | Not public |
| BB34 - WO 9006764 A1 | 2024-05-14 | Not public |
| BB31 - Chen et al. Pharmaceutical Research 2003 Vol. 20 No. 12 p. 1952-60 (Chen) | 2024-05-14 | Not public |
| BB30 - Crommelin Pharmaceutical Biotechnology Fundamentals and Applications (second edition) | 2024-05-14 | Not public |
| BB26K - Yadav et al. Pharmaceutical Research 2011 vol. 28 p. 1750-1764 submitted by letter of Novartis 26 July 2021 (Yad | 2024-05-14 | Not public |
| BB27 - Statement of Defence by Novartis in the Dutch proceedings 3 April 2024 | 2024-05-14 | Not public |
| BB26D - Letter Novartis on submission of claims 1-21 3 November 2020 | 2024-05-14 | Not public |
| BB24 - EP 4 108 259 A1 | 2024-05-14 | Not public |
| BB20 - EP 2 116 265 B1 | 2024-05-14 | Not public |
| BB26M - Letter Novartis regarding third party observation 4 October 2021 | 2024-05-14 | Not public |
| BB32 - EP 0 025 275 A2 | 2024-05-14 | Not public |
| BB26A - International search report 12 April 2006 | 2024-05-14 | Not public |
| BB23 - EP 4 104 859 A1 | 2024-05-14 | Not public |
| BB37 - EP 1 786 830 B1 | 2024-05-14 | Not public |
| BB26H - Adjusted claims 1-3 by letter of Novartis 26 July 2021 | 2024-05-14 | Not public |
| 20240515 Objection UPC Celltrion v Novartis (signed) | 2024-05-14 | Not public |
| BB22 - Technical primer for the Patent | 2024-05-14 | Not public |
| BB26J - Liu et al. Journal of Pharmaceutical Sciences 2005 vol. 94 p. 1928-1940 submitted by letter of Novartis 26 July | 2024-05-14 | Not public |
| BB21A - CV of Prof. dr. H.W. Frijlink | 2024-05-14 | Not public |
| BB26B - Letter EPO to remedy deficiencies (submission of claims) 28 October 2020 | 2024-05-14 | Not public |
| BB26C - Claims 1-21 submitted by letter of Novartis 3 November 2020 | 2024-05-14 | Not public |
| BB26I - Tomar et al. journal of the Taylor Francis Group 2017 vol. 9 p. 476-489 submitted by letter of Novartis 26 July | 2024-05-14 | Not public |
| BB29 - EP 1 610 820 B2 | 2024-05-14 | Not public |
| BB24 - EP 4 108 259 A1 | 2024-05-14 | Not public |
| BB35A - JP H04-198195 - translation of description | 2024-05-14 | Not public |
| BB27A - English machine translation of Statement of Defence by Novartis 3 April 2024 | 2024-05-14 | Not public |
| BB21 - Expert declaration of Prof. dr. H.W. Frijlink on arginine(-HCl) (Expert declaration of Prof. Frijlink I) | 2024-05-14 | Not public |
| BB23 - EP 4 104 859 A1 | 2024-05-14 | Not public |
| BB33 - WO 03072060 A2 | 2024-05-14 | Not public |
| BB27 - Statement of Defence by Novartis in the Dutch proceedings 3 April 2024 | 2024-05-14 | Not public |
| BB26D - Letter Novartis on submission of claims 1-21 3 November 2020 | 2024-05-14 | Not public |
| BB26A - International search report 12 April 2006 | 2024-05-14 | Not public |
| BB36 - Hernandez et al. 2022 | 2024-05-14 | Not public |
| BB26K - Yadav et al. Pharmaceutical Research 2011 vol. 28 p. 1750-1764 submitted by letter of Novartis 26 July 2021 (Yad | 2024-05-14 | Not public |
| BB26O - Third party observation 24 May 2022 | 2024-05-14 | Not public |
| BB21B - Annexes to the expert declaration of Prof. dr. H.W. Frijlink | 2024-05-14 | Not public |
| BB26C - Claims 1-21 submitted by letter of Novartis 3 November 2020 | 2024-05-14 | Not public |
| BB26G - Letter Novartis regarding the adjustment of the claims 26 July 2021 | 2024-05-14 | Not public |
| BB22 - Technical primer for the Patent | 2024-05-14 | Not public |
| BB31 - Chen et al. Pharmaceutical Research 2003 Vol. 20 No. 12 p. 1952-60 (Chen) | 2024-05-14 | Not public |
| BB34 - WO 9006764 A1 | 2024-05-14 | Not public |
| BB35 - JP H04-198195 | 2024-05-14 | Not public |
| BB21A - CV of Prof. dr. H.W. Frijlink | 2024-05-14 | Not public |
| BB25 - Decision of the Board of Appeal EPO on EP 636 5 May 2022 | 2024-05-14 | Not public |
| BB26B - Letter EPO to remedy deficiencies (submission of claims) 28 October 2020 | 2024-05-14 | Not public |
| 20240515 Objection UPC Celltrion v Novartis (signed) | 2024-05-14 | Not public |
| BB26N - Notice Examiner 31 January 2022 | 2024-05-14 | Not public |
| BB32 - EP 0 025 275 A2 | 2024-05-14 | Not public |
| BB26L - Third party observation 22 September 2021 | 2024-05-14 | Not public |
| BB30 - Crommelin Pharmaceutical Biotechnology Fundamentals and Applications (second edition) | 2024-05-14 | Not public |
| BB37 - EP 1 786 830 B1 | 2024-05-14 | Not public |
| BB26J - Liu et al. Journal of Pharmaceutical Sciences 2005 vol. 94 p. 1928-1940 submitted by letter of Novartis 26 July | 2024-05-14 | Not public |
| BB20 - EP 2 116 265 B1 | 2024-05-14 | Not public |
| BB26E - European Search Opinion 10 June 2021 | 2024-05-14 | Not public |
| BB26F - European Search Report 31 May 2021 | 2024-05-14 | Not public |
| BB26H - Adjusted claims 1-3 by letter of Novartis 26 July 2021 | 2024-05-14 | Not public |
| BB28 - Letter Novartis regarding submission of patentees 18 July 2022 | 2024-05-14 | Not public |
| BB26M - Letter Novartis regarding third party observation 4 October 2021 | 2024-05-14 | Not public |
| 2024-05-13 Order TQJ | 2024-05-13 | Public |
| Consent to allocation of technically qualified judge | 2024-05-13 | Not public |
| Consent to allocation of technically qualified judge | 2024-05-13 | Not public |
| Consent to the appointment of a TQJ | 2024-05-10 | Not public |
| Consent to the appointment of a TQJ | 2024-05-10 | Not public |
| Consent to the appointment of a TQJ | 2024-05-10 | Not public |
| Consent to the appointment of a TQJ | 2024-05-10 | Not public |
| Consent to the appointment of a TQJ | 2024-05-10 | Not public |
| Consent to the appointment of a TQJ | 2024-05-10 | Not public |
| Consent to the appointment of a TQJ | 2024-05-10 | Not public |
| Pre Order TQJ | 2024-05-02 | Not public |
| Repeated upload of order dated 10 April 2024 | 2024-05-02 | Not public |
| Date of a possible oral hearing | 2024-04-23 | Public |
| Acknowledgement of access to case | 2024-04-18 | Not public |
| Acknowledgement of access to case | 2024-04-18 | Not public |
| Acknowledgement of access to case | 2024-04-18 | Not public |
| Acknowledgement of access to case | 2024-04-18 | Not public |
| Acknowledgement of access to case | 2024-04-18 | Not public |
| Acknowledgement of access to case | 2024-04-18 | Not public |
| Acknowledgement of access to case | 2024-04-18 | Not public |
| Confirmation of notification of appointment | 2024-04-18 | Not public |
| Service to Defendants 1 to 7 | 2024-04-18 | Not public |
| Confirmation of notification of appointment | 2024-04-18 | Not public |
| Service to Defendants 1 to 7 | 2024-04-18 | Not public |
| Confirmation of notification of appointment | 2024-04-18 | Not public |
| Service to Defendants 1 to 7 | 2024-04-18 | Not public |
| Confirmation of notification of appointment | 2024-04-18 | Not public |
| Service to Defendants 1 to 7 | 2024-04-18 | Not public |
| Confirmation of notification of appointment | 2024-04-18 | Not public |
| Service to Defendants 1 to 7 | 2024-04-18 | Not public |
| Confirmation of notification of appointment | 2024-04-18 | Not public |
| Service to Defendants 1 to 7 | 2024-04-18 | Not public |
| Confirmation of notification of appointment | 2024-04-18 | Not public |
| Service to Defendant 1 to 7 | 2024-04-18 | Not public |
| Letter for Service | 2024-04-12 | Not public |
| Letter for Service | 2024-04-12 | Not public |
| Letter for Service | 2024-04-12 | Not public |
| Letter for Service | 2024-04-12 | Not public |
| Letter for Service | 2024-04-12 | Not public |
| Letter for Service | 2024-04-12 | Not public |
| Letter for Service | 2024-04-12 | Not public |
| Panel-Appointment | 2024-04-11 | Not public |
| R.207.8 Order | 2024-04-10 | Public |
| Panel-Appointment | 2024-04-09 | Not public |
| Application-For-Measures-Receipt | 2024-04-09 | Not public |
| Formal-checks_Notification-of-positive-outcome | 2024-04-09 | Not public |
| Receipt | 2024-04-09 | Not public |
| Application to request confidentiality from the public (RoP262.2) | 2024-04-09 | Not public |
| Application-For-Measures-Acknowledgement | 2024-04-09 | Not public |
| Exhibit FBD 14 | 2024-04-09 | Not public |
| Exhibit FBD 13 | 2024-04-09 | Not public |
| Exhibit FBD 12a | 2024-04-09 | Not public |
| Exhibit FBD 3 | 2024-04-09 | Not public |
| Application for Provisional Measures | 2024-04-09 | Not public |
| Exhibit FBD 19 | 2024-04-09 | Not public |
| Exhibit FBD 31 | 2024-04-09 | Not public |
| Exhibit FBD 12 | 2024-04-09 | Not public |
| Exhibit FBD 9 | 2024-04-09 | Not public |
| Exhibit FBD 21 | 2024-04-09 | Not public |
| Exhibit FBD 30 | 2024-04-09 | Not public |
| Exhibit FBD 24 | 2024-04-09 | Not public |
| Exhibit FBD 6 | 2024-04-09 | Not public |
| Exhibit FBD 16 | 2024-04-09 | Not public |
| Exhibit FBD 4 | 2024-04-09 | Not public |
| Exhibit FBD 2 | 2024-04-09 | Not public |
| Exhibit FBD 18 | 2024-04-09 | Not public |
| Exhibit FBD 5 (Confidential) | 2024-04-09 | Not public |
| Application for Provisional Measures | 2024-04-09 | Not public |
| Exhibit FBD 17 | 2024-04-09 | Not public |
| Exhibit FBD 25 | 2024-04-09 | Not public |
| Exhibit FBD 5 (Confidential) | 2024-04-09 | Not public |
| Exhibit FBD 1 | 2024-04-09 | Not public |
| Exhibit FBD 20 | 2024-04-09 | Not public |
| Exhibit FBD 15 | 2024-04-09 | Not public |
| Exhibit FBD 27 | 2024-04-09 | Not public |
| Exhibit FBD 26 | 2024-04-09 | Not public |
| Exhibit FBD 22 | 2024-04-09 | Not public |
| Exhibit FBD 8 | 2024-04-09 | Not public |
| Exhibit FBD 29 | 2024-04-09 | Not public |
| Exhibit FBD 23 | 2024-04-09 | Not public |
| Exhibit FBD 11 | 2024-04-09 | Not public |
| Exhibit FBD 33 | 2024-04-09 | Not public |
| Exhibit FBD 21-1 | 2024-04-09 | Not public |
| Exhibit FBD 28 | 2024-04-09 | Not public |
| Exhibit FBD 7 | 2024-04-09 | Not public |
| Exhibit FBD 10 | 2024-04-09 | Not public |
| Exhibit FBD 32 | 2024-04-09 | Not public |
Coverage: Partial.Reasoning extracted with partial coverage — some sections may be incomplete.
Plain-English summary
Novartis AG and Genentech, Inc. applied for provisional measures at the Düsseldorf Local Division against Celltrion Healthcare entities regarding EP 3 805 248 B1 (antibody concentration process related to the biosimilar Epysqli). The court rejected the application, finding the requirements for provisional measures not satisfied and awarding EUR 138,562.80 in interim costs to the defendants, while establishing important headnotes on the autonomous interpretation of UPCA, imminent infringement, group company liability, and parties' obligations to present focused technical arguments.
Accepted arguments
What the court agreed with — by party.
Court must be convinced of patent validity with sufficient certainty before granting provisional measures, including likelihood of EPO outcome
RespondentLegal basis: Art. 62(4) UPCA; R. 211.2 RoPNote: The Düsseldorf court denied provisional measures partly because the requirements for technical arguments to be focused, precise, and comprehensible were not met by the applicants.
Art. 25 UPCA constitutes uniform substantive law interpreted independently, not by reference to national patent laws
argumentParty.court (headnote)Legal basis: Art. 25 UPCANote: Court articulated that UPCA substantive and procedural law takes precedence over national patent laws and must be interpreted autonomously.
R. 295 RoP (stay of proceedings) does not apply to applications for provisional measures
RespondentLegal basis: R. 295 RoPNote: Court confirmed that R. 295 refers to main actions only, not to provisional measure applications.
Rejected arguments
What the court did not agree with — and why.
Provisional measures application for preliminary injunction against Celltrion entities regarding EP 3 805 248 B1
ClaimantLegal basis: Art. 62 UPCA; R. 211 RoPReason: Requirements for provisional measures were not met; the application was rejected in its entirety and Novartis/Genentech were ordered to pay EUR 138,562.80 in interim costs.
Key legal principles
Doctrines and rules cited in the reasoning.
Art. 25 and Art. 62 UPCA constitute uniform autonomous law superseding national patent lawImminent infringement requires preparations fully completed and infringement being only a matter of startingGroup company members playing key distribution roles can be infringers even if located outside Contracting Member StatesR. 295 RoP stay of proceedings does not apply to provisional measuresParties must present technical arguments in a focused, precise, and comprehensible form — especially in PI proceedingsClaim interpretation is mandatory for both court and parties
Browse other cases on this principle.